Bio-Rad Laboratories (NYSE:BIO.B) Shares Gap Down - Should You Sell?

Key Points

• Shares gapped down prior to trading, opening at $257.71 versus the prior close of $277.00 with only 115 shares changing hands; the article cites a 13.7% decline.
• Bio‑Rad has strong liquidity and low leverage with a quick ratio of 2.37, current ratio of 3.21 and debt‑to‑equity of 0.12, and a market capitalization of about $6.98 billion.
• The stock trades at a relatively high valuation (PE ~42.6), while recent results showed $1.89 EPS, a net margin of 6.52% and return on equity of 3.56%.

Bio-Rad Laboratories, Inc. (NYSE:BIO.B - Get Free Report)'s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $277.00, but opened at $257.71. Bio-Rad Laboratories shares last traded at $257.71, with a volume of 115 shares trading hands.

Bio-Rad Laboratories Stock Down 13.7%

The business's fifty day moving average price is $276.55 and its 200 day moving average price is $295.43. The company has a quick ratio of 2.37, a current ratio of 3.21 and a debt-to-equity ratio of 0.12. The firm has a market capitalization of $6.98 billion, a PE ratio of 42.58 and a beta of 0.96.

Bio-Rad Laboratories (NYSE:BIO.B - Get Free Report) last announced its earnings results on Thursday, April 30th. The company reported $1.89 EPS for the quarter. Bio-Rad Laboratories had a net margin of 6.52% and a return on equity of 3.56%.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of innovative products and systems that serve the life science research and clinical diagnostics markets. The company operates through two primary segments: Life Science, which delivers instruments, consumables and software for research applications, and Clinical Diagnostics, which offers quality control materials and reagent systems for blood typing, immunology and molecular testing. Bio-Rad's product portfolio supports a wide range of applications, including protein analysis, gene expression, cell biology and digital PCR.

In the Life Science segment, Bio-Rad develops and markets technologies such as electrophoresis and imaging systems, chromatography instruments, laboratory consumables and software platforms that streamline experimental workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.